Tariq Ahmad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1242971/publications.pdf

Version: 2024-02-01

131	3,420	29 h-index	53
papers	citations		g-index
131	131	131	5280
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Empagliflozin in Heart Failure. Circulation, 2020, 142, 1028-1039.	1.6	252
2	Clinical Implications of ChronicÂHeartÂFailure Phenotypes DefinedÂbyÂCluster Analysis. Journal of the American College of Cardiology, 2014, 64, 1765-1774.	2.8	197
3	Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. Journal of the American Heart Association, 2018, 7, .	3.7	153
4	Machine Learning Prediction of Mortality and Hospitalization in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 12-21.	4.1	152
5	Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical CirculatoryÂSupport. Journal of the American College of Cardiology, 2016, 67, 291-299.	2.8	143
6	Trends in 30- and 90-Day Readmission Rates for Heart Failure. Circulation: Heart Failure, 2021, 14, e008335.	3.9	113
7	Rationale and Design of theÂGUIDE-ITÂStudy. JACC: Heart Failure, 2014, 2, 457-465.	4.1	106
8	Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure. JACC: Heart Failure, 2014, 2, 260-268.	4.1	104
9	Hypochloremia and Diuretic Resistance in Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	102
10	Reduced Cardiac Index Is Not theÂDominant Driver of RenalÂDysfunctionÂinÂHeart Failure. Journal of the American College of Cardiology, 2016, 67, 2199-2208.	2.8	98
11	Electronic Alerts to Improve HeartÂFailure Therapy in Outpatient Practice. Journal of the American College of Cardiology, 2022, 79, 2203-2213.	2.8	86
12	Lifestyle Interaction With Fat Mass and Obesity-Associated (<i>FTO</i>) Genotype and Risk of Obesity in Apparently Healthy U.S. Women. Diabetes Care, 2011, 34, 675-680.	8.6	84
13	Charting a Roadmap for Heart Failure Biomarker Studies. JACC: Heart Failure, 2014, 2, 477-488.	4.1	81
14	Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. European Journal of Heart Failure, 2019, 21, 1064-1078.	7.1	79
15	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. JAMA Cardiology, 2020, 5, 757.	6.1	74
16	Effects of Left Ventricular Assist Device Support on Biomarkers of Cardiovascular Stress, Fibrosis, FluidÂHomeostasis, Inflammation, and Renal Injury. JACC: Heart Failure, 2015, 3, 30-39.	4.1	70
17	Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy. JACC: Heart Failure, 2021, 9, 420-429.	4.1	64
18	Real World Use of Hypertonic Saline in Refractory Acute Decompensated HeartÂFailure. JACC: Heart Failure, 2020, 8, 199-208.	4.1	59

#	Article	IF	Citations
19	Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study. PLoS Medicine, 2016, 13, e1002007.	8.4	55
20	National Trends in Use and Outcomes of Pulmonary Artery Catheters Among Medicare Beneficiaries, 1999-2013. JAMA Cardiology, 2017, 2, 908.	6.1	54
21	The Fat-Mass and Obesity-Associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women. American Heart Journal, 2010, 160, 1163-1169.	2.7	51
22	Challenges Facing Early Career Academic Cardiologists. Journal of the American College of Cardiology, 2014, 63, 2199-2208.	2.8	51
23	Natriuretic Response Is Highly Variable and Associated With 6-Month Survival. JACC: Heart Failure, 2019, 7, 383-391.	4.1	51
24	The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. American Heart Journal, 2014, 167, 193-202.e1.	2.7	50
25	Predictive Abilities of Machine Learning Techniques May Be Limited by Dataset Characteristics: Insights From the UNOS Database. Journal of Cardiac Failure, 2019, 25, 479-483.	1.7	48
26	Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. Circulation: Heart Failure, 2019, 12, e005552.	3.9	43
27	Trends in Heart Failure Hospitalizations in the US from 2008 to 2018. Journal of Cardiac Failure, 2022, 28, 171-180.	1.7	40
28	Sex Differences in Patients Receiving Left Ventricular Assist Devices for End-Stage HeartÂFailure. JACC: Heart Failure, 2020, 8, 770-779.	4.1	36
29	Conduct of Clinical Trials in the Era of COVID-19. Journal of the American College of Cardiology, 2020, 76, 2368-2378.	2.8	35
30	Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes. ESC Heart Failure, 2021, 8, 2741-2754.	3.1	32
31	When the Heart Runs Out of Heartbeats. Circulation, 2012, 125, 2948-2955.	1.6	30
32	Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles. PLoS ONE, 2016, 11, e0145881.	2.5	30
33	Relationship Between Galectin-3 Levels and Mineralocorticoid Receptor Antagonist Use in Heart Failure: Analysis From HF-ACTION. Journal of Cardiac Failure, 2014, 20, 38-44.	1.7	28
34	An exploratory analysis of the competing effects of aggressive decongestion and high-dose loop diuretic therapy in the DOSE trial. International Journal of Cardiology, 2017, 241, 277-282.	1.7	27
35	Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. Circulation: Heart Failure, 2018, 11, e004926.	3.9	26
36	Clinical Outcomes After Left Ventricular Assist Device Implantation in Older Adults. JACC: Heart Failure, 2019, 7, 1069-1078.	4.1	25

#	Article	IF	CITATIONS
37	Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry). American Journal of Cardiology, 2021, 146, 99-106.	1.6	25
38	Inflammation and cardioâ€renal interactions in heart failure: a potential role for interleukinâ€6. European Journal of Heart Failure, 2018, 20, 933-934.	7.1	24
39	Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. JAAD Case Reports, 2019, 5, 1018-1026.	0.8	24
40	Improving Outcomes in INTERMACS Category 1 Patients with Pre-LVAD, Awake Venous-Arterial Extracorporeal Membrane Oxygenation Support. ASAIO Journal, 2019, 65, 819-826.	1.6	22
41	Clinical impact of concomitant tricuspid valve procedures during left ventricular assist device implantation. Journal of Heart and Lung Transplantation, 2020, 39, 926-933.	0.6	21
42	COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system. PLoS ONE, 2020, 15, e0238829.	2.5	21
43	Acute Decompensated Heart Failure Complicated by Respiratory Failure. Circulation: Heart Failure, 2019, 12, e006013.	3.9	20
44	Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications. Cardiovascular Endocrinology and Metabolism, 2020, 9, 56-59.	1.1	20
45	The Role of Sodium and Chloride inÂHeartÂFailure. Journal of the American College of Cardiology, 2015, 66, 667-669.	2.8	19
46	Trends in Performance and Opportunities for Improvement on a Composite Measure of Acute Myocardial Infarction Care. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004983.	2.2	19
47	Use of outcome measures in pulmonary hypertension clinical trials. American Heart Journal, 2015, 170, 419-429.e3.	2.7	17
48	National Trends in Healthcare-Associated Infections for Five Common Cardiovascular Conditions. American Journal of Cardiology, 2019, 124, 1140-1148.	1.6	17
49	Nudging within learning health systems: next generation decision support to improve cardiovascular care. European Heart Journal, 2022, 43, 1296-1306.	2.2	16
50	Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports, 2017, 14, 434-443.	3.3	15
51	Evaluation of Case Volumes of a Heart Transplant Program and Short-term Outcomes After Changes in the United Network for Organ Sharing Donor Heart Allocation System. JAMA Network Open, 2020, 3, e2017513.	5.9	14
52	REVeAL-HF. JACC: Heart Failure, 2021, 9, 409-419.	4.1	14
53	National Trends in Incidence and Outcomes of Patients With Heart Failure Requiring Respiratory Support. American Journal of Cardiology, 2019, 124, 1712-1719.	1.6	13
54	Clinical Implications of Respiratory Failure in Patients Receiving Durable Left Ventricular Assist Devices for End-Stage Heart Failure. Circulation: Heart Failure, 2019, 12, e006369.	3.9	13

#	Article	IF	CITATIONS
55	Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation. American Journal of Cardiology, 2020, 133, 116-125.	1.6	13
56	Quadruple Therapy Is the New Standard of Care for HFrEF. JACC: Heart Failure, 2020, 8, 819-821.	4.1	13
57	Association between Respiratory Failure and Clinical Outcomes in Patients with Acute Heart Failure: Analysis of 5 Pooled Clinical Trials. Journal of Cardiac Failure, 2021, 27, 602-606.	1.7	13
58	Trends in transcatheter and surgical aortic valve replacement in the United States, 2008-2018. American Heart Journal, 2022, 243, 87-91.	2.7	13
59	Novel approach to classifying patients with pulmonary arterial hypertension using cluster analysis. Pulmonary Circulation, 2017, 7, 486-493.	1.7	12
60	National Landscape of Unplanned 30-Day Readmissions in Patients With Left Ventricular Assist Device Implantation. American Journal of Cardiology, 2018, 122, 261-267.	1.6	12
61	Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers about treatment of heart failure (PROMPT-HF). American Heart Journal, 2022, 244, 107-115.	2.7	12
62	A Blueprint for the Post Discharge Clinic Visit after an Admission for Heart Failure. Progress in Cardiovascular Diseases, 2017, 60, 237-248.	3.1	11
63	The Twittersphere Needs AcademicÂCardiologists!. JACC: Heart Failure, 2018, 6, 172-173.	4.1	11
64	The Trifecta of Precision Care in HeartÂFailure. Journal of the American College of Cardiology, 2018, 72, 1091-1094.	2.8	11
65	Transition to Advanced Therapies in Elderly Patients Supported by Extracorporeal Membrane Oxygenation Therapy. Journal of Cardiac Failure, 2020, 26, 1086-1089.	1.7	11
66	Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies. PLoS ONE, 2021, 16, e0247789.	2.5	11
67	The Current and Potential Clinical Relevance of Heart Failure Biomarkers. Current Heart Failure Reports, 2015, 12, 318-327.	3.3	10
68	Psychiatric Comorbidity and Outcomes After Left Ventricular Assist Device Implantation for End-Stage HeartÂFailure. JACC: Heart Failure, 2020, 8, 569-577.	4.1	10
69	Multisystem inflammatory syndrome in adults (MIS-A) associated with SARS-CoV-2 infection with delayed-onset myocarditis: case report. European Heart Journal - Case Reports, 2021, 5, ytab470.	0.6	10
70	Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. Circulation: Heart Failure, 2015, 8, 709-716.	3.9	9
71	Left Ventricular Assist Devices Versus Heart Transplantation for End Stage HeartÂFailure is a Misleading Equivalency. JACC: Heart Failure, 2021, 9, 290-292.	4.1	9
72	Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. PLoS ONE, 2020, 15, e0242928.	2.5	9

#	Article	IF	CITATIONS
73	Can Big Data Simplify the ComplexityÂofÂModern Medicine?. JACC: Heart Failure, 2016, 4, 722-725.	4.1	8
74	Mechanical ventilation at the time of heart transplantation and associations with clinical outcomes. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 843-851.	1.0	8
75	Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes. JACC: Heart Failure, 2021, 9, 568-577.	4.1	8
76	Reimagining Evidence Generation for Heart Failure and the Role of Integrated Health Care Systems. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, CIRCOUTCOMES121008292.	2.2	8
77	Essential Elements of Early Post Discharge Care of Patients with Heart Failure. Current Heart Failure Reports, 2018, 15, 181-190.	3.3	7
78	Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). American Journal of Cardiology, 2019, 123, 1193-1201.	1.6	7
79	Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 447-455.	2.4	7
80	Outcomes in patients with anthracyclineâ€induced cardiomyopathy undergoing left ventricular assist devices implantation. ESC Heart Failure, 2021, 8, 2866-2875.	3.1	7
81	Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008594.	3.9	7
82	Disentangling the association between statins, cholesterol, and colorectal cancer: A nested case-control study Journal of Clinical Oncology, 2016, 34, 3609-3609.	1.6	6
83	Wherein Lies the Balance Between CaringÂand Detachment?. Journal of the American College of Cardiology, 2015, 65, 1481-1483.	2.8	5
84	Breaking Bad. JACC: Heart Failure, 2017, 5, 446-448.	4.1	5
85	Safety of compression therapy for venous ulcer disease in the setting of congestive heart failure. Phlebology, 2020, 35, 556-560.	1.2	5
86	A Novel Treatment for a Rare Cause of Cardiogenic Shock. JACC: Case Reports, 2020, 2, 1461-1465.	0.6	5
87	Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With HeartÂFailure. JACC: Heart Failure, 2021, 9, 497-505.	4.1	5
88	Electronic health record risk score provides earlier prognostication of clinical outcomes in patients admitted to the cardiac intensive care unit. American Heart Journal, 2021, 238, 85-88.	2.7	5
89	Trends and Outcomes of Cardiac Transplantation in the Lowest Urgency Candidates. Journal of the American Heart Association, 2021, 10, e023662.	3.7	5
90	Potential Applications of Pharmacogenomics to Heart Failure Therapies. Heart Failure Clinics, 2014, 10, 599-606.	2.1	4

#	Article	IF	CITATIONS
91	Reclassifying heart failure: time for disruptive innovation?. European Journal of Heart Failure, 2015, 17, 879-880.	7.1	4
92	Haemoconcentration as a treatment goal in heart failure: ready for prime time?. European Journal of Heart Failure, 2017, 19, 237-240.	7.1	3
93	Variation in practice patterns and outcomes across United Network for Organ Sharing allocation regions. Clinical Cardiology, 2018, 41, 81-86.	1.8	3
94	Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. Circulation: Heart Failure, 2021, 14, e007759.	3.9	3
95	Brief report: Cannabis and opioid use disorder among heart failure admissions, 2008–2018. PLoS ONE, 2021, 16, e0255514.	2.5	3
96	Impact of Preoperative Lymphopenia on Survival Following Left Ventricular Assist Device Placement. ASAIO Journal, 2021, 67, 650-657.	1.6	3
97	The influence of comorbidities on achieving an Nâ€terminal proâ€bâ€type natriuretic peptide target: a secondary analysis of the GUIDEâ€IT trial. ESC Heart Failure, 2021, , .	3.1	3
98	Thirty-Day and 90-Day Episode of Care Spending Following Heart Failure Hospitalization Among Medicare Beneficiaries. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	2.2	3
99	Disrupting Virchow's triad: can factor X inhibition reduce risk of adverse outcomes in patients with ischaemic cardiomyopathy?. European Journal of Heart Failure, 2015, 17, 647-651.	7.1	2
100	Physical Activity Prevents Obesity andÂHeart Failure. JACC: Heart Failure, 2017, 5, 385-387.	4.1	2
101	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. European Cardiology Review, 2021, 16, e11.	2.2	2
102	The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. Journal of Cardiac Failure, 2021, 27, 1359-1366.	1.7	2
103	Cannabis use disorder among atrial fibrillation admissions, 2008–2018. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 1934-1938.	1.2	2
104	The Heart Is Just a Muscle. Circulation, 2015, 131, 914-922.	1.6	1
105	Loop diuretics in heart failure: Few facts and lots of prejudice. American Heart Journal, 2018, 205, 131-132.	2.7	1
106	Combating Acute Heart Failure inÂtheÂArena. JACC: Heart Failure, 2018, 6, 871-873.	4.1	1
107	HeartÂFailure With PreservedÂEjectionÂFraction. JACC: Heart Failure, 2020, 8, 185-187.	4.1	1
108	Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer. American Heart Journal, 2020, 230, 54-58.	2.7	1

#	Article	IF	Citations
109	Under Our Very Eyes. New England Journal of Medicine, 2020, 382, 952-957.	27.0	1
110	Adoption of sacubitril-valsartan in the Medicare population. American Heart Journal, 2020, 223, 81-83.	2.7	1
111	Impact of left ventricular assist devices and heart transplants on acute myocardial infarction and heart failure mortality and readmission measures. PLoS ONE, 2020, 15, e0230734.	2.5	1
112	Comparison of Transcatheter and Open Mitral Valve Repair Among Patients With Mitral Regurgitation. Mayo Clinic Proceedings, 2021, 96, 1522-1529.	3.0	1
113	Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. Progress in Cardiovascular Diseases, 2022, , .	3.1	1
114	Treatment for low-risk patients with STEMIâ€"challenges remain. Nature Reviews Cardiology, 2014, 11, 440-442.	13.7	0
115	What happens to stable heart failure patients when they don't take their medicines?. European Journal of Heart Failure, 2017, 19, 650-651.	7.1	0
116	Can advanced analytics fix modern medicine's problem of uncertainty, imprecision, and inaccuracy?. European Journal of Heart Failure, 2019, 21, 86-89.	7.1	0
117	Use and outcomes of wearable cardioverter-defibrillators in a large integrated academic health system. American Heart Journal, 2020, 226, 232-234.	2.7	0
118	Setting the Stage for a Multimarker-Based HeartÂFailure Prevention Trial?. JACC: Heart Failure, 2021, 9, 224-225.	4.1	0
119	Extreme High Insulin Requirements in Two Non-Diabetic Patients Following Cardiac Transplantation. Journal of the Endocrine Society, 2021, 5, A383-A383.	0.2	0
120	Reply. JACC: Heart Failure, 2021, 9, 532.	4.1	0
121	Electrocardiogram Findings in Patients with Alopecia Areata. Dermatology and Therapy, 2021, 11, 2217-2223.	3.0	0
122	Title is missing!. , 2020, 15, e0230734.		0
123	Title is missing!. , 2020, 15, e0230734.		0
124	Title is missing!. , 2020, 15, e0230734.		0
125	Title is missing!. , 2020, 15, e0230734.		0
126	Title is missing!. , 2020, 15, e0230734.		0

Tariq Ahmad

#	Article	IF	CITATIONS
127	Title is missing!. , 2020, 15, e0230734.		O
128	Title is missing!. , 2020, 15, e0238829.		0
129	Title is missing!. , 2020, 15, e0238829.		O
130	Title is missing!. , 2020, 15, e0238829.		0
131	Title is missing!. , 2020, 15, e0238829.		O